Starving cancer by hijacking the body's own immune system

Health · Published 18 October 2026 Swipe more like this →

In short: Most lung cancers thrive by hijacking a growth signal called EGF. Instead of attacking the tumor directly, CIMAvax-EGF is an immunotherapy designed to trick the body into producing antibodies that neutralize this signal. By depleting the growth stimulus from the blood, it effectively starves the cancer cells.

Non-small cell lung cancer (NSCLC) is characterized by the overexpression of the epidermal growth factor receptor (EGFR). In roughly 75-85% of NSCLC cases, this receptor is overactive because it is constantly being fed by its ligand, EGF. This interaction promotes malignant transformation, cell proliferation, and survival. Rather than using traditional chemotherapy to kill cells directly, CIMAvax-EGF functions as an 'EGF-depleting' immunotherapy.

Developed in Cuba, the vaccine works by chemically conjugating recombinant human EGF with a protein carrier (P64) from Neisseria meningitides and using Montanide ISA51 as an adjuvant. The goal is to induce neutralizing antibodies against self-EGF. To boost this reaction, a minor amount of cyclophosphamide is frequently administered to patients 3 days prior to inoculation; it is believed that this briefly inhibits the internal immune system's tolerance toward its own EGF, facilitating greater antibody levels.

Real-world studies in Cuba have shown that CIMAvax-EGF can serve as an effective maintenance therapy after first-line treatments like platinum-based chemotherapy. In one study of 106 patients with advanced NSCLC, the median survival time was 14.6 months, with those under 65 years old reaching a median survival of 16.7 months. While some experts suggest it might be most effective as a preventive measure, its use in primary care settings has demonstrated feasibility for managing advanced cases where patients are no longer eligible for complex therapies.

The vaccine is noted for being relatively inexpensive to manufacture—costing approximately US$1 per shot—and having low toxicity. Common side effects are generally mild, including fever, chills, and injection site reactions like pain or erythema. Its ability to be administered in community polyclinics by family doctors reduces the burden on specialized oncology services while providing a maintenance option for patients with deteriorating conditions.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Can a virus be the ultimate weapon against cancer?
• How a New York cancer center pioneered the era of living drugs
• Why we are moving from systemic chemotherapy to precision immune hacking
• Can a 60-second injection revolutionize cancer care for thousands?
• The molecular gatekeepers that decide which cellular secrets are exposed
• The precise angle where light loses its ability to reflect
• The master switch that tells your body how to fight infection
• The hidden psychological signals of anthrax vaccination
• The laboratory of hygiene that shaped modern immunology
• The 1954 test of the polio vaccine involved 1.8 million children.
• A maternal vaccine that creates a shield for the unborn
• The chemical switch that controls your skin's color and vision

More in Vaccines · More in Health · Latest · A–Z · All topics